Welcome to our forum, here you will find many wonderful caring individuals
who walk the cancer journey or are care givers to loved one's.
I have been searching the web for a few hour's now trying to obtain as much
information as I can. I was able to only acquire a little on Thalidomide,
perhaps if you contact the NCI @ 1-800-4-cancer they may be of further
help. However, I did find some information on a particular treatment for
adnoid cystic carcinoma that looked promising to me and thought you may
want to investigate it. Your friend, lillian
WASHINGTON (Reuters) - Thalidomide, once banned in the U.S. for.causing
birth defects but enjoying renewed interest as a treatment
for diseases ranging from leprosy to AIDS, got approval for
experimental use against cancer Friday. The U.S. Food and Drug
Administration gave New Jersey-based Celgene Corp. orphan drug
designation for Thalomid, its version of Thalidomide, the company
said. This gives Celgene clearance to test Thalomid against multiple
myeloma, the most common form of bone marrow cancer. Orphan drug
designation is intended to encourage research and development of new
therapies for diseases affecting fewer than 200,000 Americans
Welcome to the Fermilab Neutron Therapy Facility WWW server!
The Fermilab Neutron Therapy Facility utilizes a beam of high energy
neutrons to treat malignant tumors. The neutron beam is formed by
bombarding a beryllium target with 66 MeV protons, which are deflected from
Fermilab's linear accelerator. Patient's tumors are irradiated by placing
the tumor volume accurately in the neutron beam and localizing the beam as
closely as possible to the contours of the tumor using collimators.
What was once considered to be purely experimental has now become the
treatment of choice for certain malignant tumors. Close evaluation of
patient response to this treatment modality has clearly identified that
neutrons now have a well-established place in the treatment of a number of
specific human cancers, particularly salivary gland tumors, malignant
melanomas, soft tissue sarcomas, advanced prostate cancer, and advanced
mouth and throat cancers. Continuing treatment programs will improve the
statistical evaluation of these well-established procedures as well as
continuing investigation of the treatment of other tumors including bone
sarcomas, locally advanced bladder cancers, recurrent rectal and colon
cancers, carcinomas of the lung, and glioblastoma multiforme.
For a more thorough introduction see our pamphlet - Neutrons Against Cancer
Below are links to more information about Fermilab's Neutron Therapy
Facility including information about referrals.
•Clinical Information
•Results with Prostate Patients - incl. PSA info.
•Semi-annual Newsletter(of particular interest to physicians) (Rev. June
30, 1997)
•List of Protocols
•Referring patients to NTF for neutron therapy. (including contacts for
further information)
•We are located approximately 35 miles west of Chicago, Illinois.
click here for directions
------------------------------------------------------------------------
Midwest Institute for Neutron Therapy at Fermilab
P.O. Box 5004, MS 301
Batavia, Il 60510-0500
Phone: (630) 840-3865
Fax : (630) 840-8766
------------------------------------------------------------------------
this page maintained by kroc@fnal.gov (www issues)
------------------------------------------------------------------------
<Picture>Fermilab Home Page
------------------------------------------------------------------------
------------------------------------------------------------------------
Protocol for Salivary Gland Cancers
•Squamous cell carcinoma •Adenoid cystic carcinoma •Mucoepidermoid
carcinoma •Not otherwise specified adenocarcinoma •Malignant mixed tumor
•Aggressive benign mixed tumor •Aggressive benign fibroxanthoma
Patients with these diagnoses would be given a course of neutron therapy
over twelve treatments using an appropriate technique, most likely wedged
pair.
Treatment Group A: These patient would include newly diagnosed patients
with unresectable disease, or residual disease following surgery. A planned
dose of 20.4 neutron Gy would be given at a daily dose of 1.7 Gy.
Treatment Group B: Patients with recurrent salivary gland malignancy of the
above histologic types who are recurrent after initial surgery,
re-operated, and have residual disease. A planned dose of 20.4 neutron Gy
will be given at a daily dose of 1.7 Gy.
Treatment Group C: Patients who have no gross residual disease following
surgery but are considered at risk for recurrence. These patients will be
given a dose of 19.2 Gy in twelve fractions at a rate of 1.6 Gy per
treatment.
Treatment Group D: Patients who have undergone both previous surgery and
previous radiation therapy, and have residual or recurrent disease. Such
patients will be given a dose of 19.2 Gy to 20.4 Gy with a daily dose of
1.65 to 1.7 Gy per treatment.
Rev. 6/96
Treatment with radiation therapy may involve either external beam treatment
or brachytherapy, a technique in which radiotherapeutic seeds are implanted
directly in a tumor. In some cases, both approaches are used. New
three-dimensional methods of delivering external beam radiation also now
allow for very precise delivery of radiation therapy to tumors, which helps
to avoid damage to healthy tissues and makes possible the use of higher
doses of radiation. Radiation therapy is often given in conjunction with
surgical treatment, but studies are showing that in some circumstances,
radiation therapy alone (sometimes combined with chemotherapy) is just as
effective as surgery. These new approaches can often preserve the ability
to speak and swallow normally even in patients with advanced disease.
------------------------------------------------------------------------
<Picture>Return to MINT / NTF Home Page
------------------------------------------------------------------------
this page maintained by kroc@fnal.gov (www issues)
----------
> From: KWeeks4696@AOL.COM
> To: mol-cancer@lists.meds.com
> Subject: [MOL] (no subject)
> Date: Friday, December 25, 1998 9:24 PM
>
> PLEASE SEND INFORMATION ON THALAMIDE REGARDING TREATMENT OF
> ADLNOID CYSTIC CARCINOMA
> ------------------------------------------------------------------------
> This is an automatically-generated notice. If you'd like to be removed
> from the mailing list, please visit the Medicine-On-Line Discussion Forum
> at <http://www.meds.com/con_faq.html>, or send an email message to:
> majordomo@lists.meds.com
> with the subject line blank and the body of the message containing the
line:
> unsubscribe mol-cancer your-email-address
> where the phrase your-email-address is replaced with your actual email
> address.
> ------------------------------------------------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
